苯并-1,3-二恶烷或苯并-1,3-氧杂蒽1 [由2-羟基或2-巯基苄基醇(分别为3或4)和羰基化合物容易制得]与过量的锂和α在室温或-78°C下,DTBB在THF中的催化量(4.5摩尔%)导致水解后生成相应的均苄醇2。在酸性(85%H 3 PO 4)或中性(Ph 3 P / DIAD)条件下将化合物2环化,可得到预期的杂环5。
苯并-1,3-二恶烷或苯并-1,3-氧杂蒽1 [由2-羟基或2-巯基苄基醇(分别为3或4)和羰基化合物容易制得]与过量的锂和α在室温或-78°C下,DTBB在THF中的催化量(4.5摩尔%)导致水解后生成相应的均苄醇2。在酸性(85%H 3 PO 4)或中性(Ph 3 P / DIAD)条件下将化合物2环化,可得到预期的杂环5。
MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
申请人:Miller Mark Thomas
公开号:US20170196862A2
公开(公告)日:2017-07-13
The present invention features a compound of formula I:
or a pharmaceutically acceptable salt thereof, where R
1
, R
2
, R
3
, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.
US9782408B2
申请人:——
公开号:US9782408B2
公开(公告)日:2017-10-10
New homologation of 2-hydroxy and 2-mercapto benzylic alcohols
作者:Prabir K. Choudhury、Juan Almena、Francisco Foubelo、Miguel Yus
DOI:10.1016/s0040-4020(97)10161-2
日期:1997.12
or benzo-1,3-oxathianes 1 [easily prepared from 2-hydroxy or 2-mercapto benzylic alcohols (3 or 4, respectively) and carbonyl compounds] with an excess of lithium and a catalytic amount of DTBB (4.5 mol %) in THF at room temperature or −78°C leads, after hydrolysis with water, to the corresponding homobenzylic alcohols 2. Cyclisation of compounds 2 under acidic (85% H3PO4) or neutral (Ph3P/DIAD) conditions
苯并-1,3-二恶烷或苯并-1,3-氧杂蒽1 [由2-羟基或2-巯基苄基醇(分别为3或4)和羰基化合物容易制得]与过量的锂和α在室温或-78°C下,DTBB在THF中的催化量(4.5摩尔%)导致水解后生成相应的均苄醇2。在酸性(85%H 3 PO 4)或中性(Ph 3 P / DIAD)条件下将化合物2环化,可得到预期的杂环5。